CN102813638A - Preparation method of dexketoprofen trometamol double-layer sustained-release tablets - Google Patents
Preparation method of dexketoprofen trometamol double-layer sustained-release tablets Download PDFInfo
- Publication number
- CN102813638A CN102813638A CN2011101500523A CN201110150052A CN102813638A CN 102813638 A CN102813638 A CN 102813638A CN 2011101500523 A CN2011101500523 A CN 2011101500523A CN 201110150052 A CN201110150052 A CN 201110150052A CN 102813638 A CN102813638 A CN 102813638A
- Authority
- CN
- China
- Prior art keywords
- layer
- double
- release
- dexketoprofen trometamol
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QUZMDHVOUNDEKW-MERQFXBCSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;(2s)-2-(3-benzoylphenyl)propanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 QUZMDHVOUNDEKW-MERQFXBCSA-N 0.000 title claims abstract description 40
- 229960005448 dexketoprofen trometamol Drugs 0.000 title claims abstract description 40
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003085 diluting agent Substances 0.000 claims abstract description 12
- 239000000314 lubricant Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000003826 tablet Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000011230 binding agent Substances 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 238000007605 air drying Methods 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 238000001125 extrusion Methods 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000013558 reference substance Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000011978 dissolution method Methods 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- BAZVSMNPJJMILC-UHFFFAOYSA-N triadimenol Chemical compound C1=NC=NN1C(C(O)C(C)(C)C)OC1=CC=C(Cl)C=C1 BAZVSMNPJJMILC-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract 5
- 239000012730 sustained-release form Substances 0.000 abstract 5
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 229920003081 Povidone K 30 Polymers 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to dexketoprofen trometamol double-layer sustained-release tablets and a preparation method thereof. The tablets are characterized in that the tablets are double-layer tablets obtained by compacting a fast-release layer and a sustained-release layer. The fast-release layer is mainly composed of dexketoprofen trometamol, a disintegrating agent, a diluent agent, an adhesive, and a lubricant. The sustained-release layer is mainly composed of dexketoprofen trometamol, a sustained-release material, a diluent agent, an adhesive, and a lubricant. An effective dosage of dexketoprofen trometamol is 10mg-120mg. A main medicine content ratio of the fast-release layer to the sustained-release layer is 1:(1-5). The invention also provides a preparation method of the dexketoprofen trometamol double-layer sustained-release tablets, and a release-degree testing method of the tablets. With the release of the fast-release part of the dexketoprofen trometamol double-layer sustained-release tablets provided by the invention, an effective blood concentration of the medicine can be reached fast. The sustained-release part is released slowly for maintaining a stable and uniform effective blood concentration. Therefore, medication times can be reduced, patient compliance can be improved, the treatment effect is stable, and toxic and side effects are low.
Description
Technical field
The present invention relates to a kind of new drug formulation preparation of nonsteroidal anti-inflammatory drug preparation category; Be particularly related to a kind of method for preparing of dexketoprofen trometamol double-layer sustained release tablets; It is characterized in that it being the double-layer tablet that is pressed into jointly by release layer and slow release layer, belong to field of medicaments.
Background technology
Double-layer sustained release tablets is that one or both medicines are processed the Tabules of being made up of jointly release layer and slow release layer two parts.Release layer and slow release layer can be medicine of the same race, also can have synergistic medicine for two kinds.Release layer can play one to disease at short notice to be alleviated or therapeutical effect fast, reduces the harm that seizure of disease brings patient, and slow release layer is used to keep intravital blood drug level, and symptoms plays an effect that continues to keep curative effect.This preparation not only can reduce medicining times, can also let patient can not produce bigger dependence effect to some drugs, and can reduce the peak valley difference of medicine, and rapid release and slow release effect are perfectly combined
Ketoprofen belongs to NSAID, is applicable to analgesicly, alleviates moderate pain such as arthritis, neuralgia, myalgia, headache, migraine, toothache, flu and flu-like symptom; Often use its raceme to treat all types of arthritis, postoperative pain, cancer pain and acute gout etc. clinically; But existing research proof, left-handed ketoprofen is the nonactive laevoisomer of ketoprofen, no analgesic, analgesia and antiinflammatory action are the main causes of raceme KPF generation gastrointestinal reaction; And d-isomer is the main component of performance therapeutical effect, and its activity is 2 times of racemic modification; But, its water soluble drug, i.e. dexketoprofen trometamol have been prepared because dexketoprofen is an insoluble drug at present; It can absorb rapidly and distribute in vivo, and the specific activity free acid is high, and its Cmax specific ionization acid is high; The acid of Tmax specific ionization is little, is beneficial to the treatment of acute sharp pain, and it is little to the acid of gastrointestinal toxicity specific ionization in addition; The patient there is better toleration, has broad clinical application prospect.
But the existing clinically dexketoprofen trometamol preparation half-life is short, and general formulation needs day clothes three to four times, and blood concentration fluctuation is bigger, and its slow releasing preparation release is slow, can not discharge active constituents of medicine rapidly, makes maximum plasma concentration lower; And the quick stripping of dexketoprofen trometamol in the release layer and relief of symptoms rapidly behind the double-layer sustained release preparation oral of our development; Slow release layer then slowly discharges, and the easing pain and diminishing inflammation effect was kept 12 hours, reduces medicining times; Improve patient's compliance, and alleviated untoward reaction.
Summary of the invention
The object of the present invention is to provide a kind of dexketoprofen trometamol double-layer sustained release tablets, wherein the release of immediate release section can make medicine reach effective blood drug concentration quickly, and slow-released part slowly discharges, and performance is kept steadily, uniform effective blood drug concentration.Thereby reach the minimizing medicining times, increase patient's compliance and stable curative effect, the effect that toxic and side effects is little.
For solving the problems of the technologies described above, technical scheme provided by the invention is:
The double-layer sustained release tablets of dexketoprofen trometamol provided by the invention comprises slow release layer and release layer; It is characterized in that: said slow release layer mainly is made up of dexketoprofen trometamol, disintegrating agent, diluent; Binding agent; Lubricant is formed, and said slow release layer mainly is made up of dexketoprofen trometamol, slow-release material, diluent, binding agent, lubricant.
Described double-layer sustained release tablets, the effective dose of dexketoprofen trometamol are 10mg～120mg.
The ratio that described double-layer sustained release tablets, its release layer and slow release layer contain the principal agent amount is 1: (1～5).
Described double-layer sustained release tablets; It is characterized in that said slow-release material can select one or more in hydroxypropyl methylcellulose, ethyl cellulose, methylcellulose, phthalic acid hydroxypropyl methylcellulose, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, cellulose diacetate, Triafol T, hexadecanol, glyceryl monostearate, Brazil wax, the hydroxy methocel for use, preferred hydroxypropyl methylcellulose and ethyl cellulose.
Described double-layer sustained release tablets, one or more that it is characterized in that described disintegrating agent can select that cross linked polyvinyl pyrrolidone, carboxymethyl starch are received for use, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl cellulose are received, preferred cross-linked carboxymethyl cellulose is received.
Described double-layer sustained release tablets; It is characterized in that described diluent can select lactose, pregelatinized Starch, microcrystalline Cellulose, mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol for use, gather in O-phthalic acid ethyl acetate, Polyethylene Glycol, the ethanol one or more, preferred lactose, microcrystalline Cellulose.
Described double-layer sustained release tablets; It is characterized in that in the optional water of described binding agent, ethanol, dehydrated alcohol, starch slurry, polyvidone, cross linked polyvinyl pyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families one or more, preferred cross linked polyvinyl pyrrolidone.
Described double-layer sustained release tablets is characterized in that described lubricant can select one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, the sodium laurylsulfate for use, preferred magnesium stearate.
Described double-layer sustained release tablets is characterized in that counting by weight percentage, and it consists of:
Release layer:
Slow release layer:
The present invention also provides the method for preparing of dexketoprofen trometamol double-layer sustained release tablets, it is characterized in that: this method may further comprise the steps:
1, immediate-release granules preparation
Each component that takes by weighing recipe quantity is crossed 100 mesh sieves respectively, then with crude drug, diluent, disintegrating agent mix homogeneously, and with binding agent system soft material, 20 mesh sieve system wet granulars, 60 ℃ of forced air dryings, 20 mesh sieve granulate add the lubricant mixing, get the release layer granule.
2, slow-releasing granules preparation
Each component that takes by weighing recipe quantity is crossed 100 mesh sieves respectively, then with crude drug, slow-release material, diluent, mix homogeneously, and with binding agent system soft material, 20 mesh sieve system wet granulars, 60 ℃ of forced air dryings, 20 mesh sieve granulate add the lubricant mixing, get the slow release layer granule.
3, tabletting
Light earlier pressure release layer granule becomes loose, adds the extrusion forming of slow release layer granule again, promptly gets double-layer tablet.
Described double-layer sustained release tablets is characterized in that, said double-layer sustained release tablets is according to the device of dissolution method (2010 editions two appendix XC second methods of Chinese Pharmacopoeia), and 900mL is a solvent with distilled water (pH7); Rotating speed is that per minute 100 changes, and temperature is 37 ℃, in accordance with the law operation;, respectively at 0.5,1.0,2.0,4.0,6.0,8.0, the 12.0h sampling, each 5mL;,, and in time in process container, replenish above-mentioned solvent with volume with the filtering with microporous membrane of aperture 0.45 μ m; And be mixed with finite concentration, as need testing solution; It is an amount of that precision takes by weighing the dexketoprofen trometamol reference substance in addition, with above-mentioned solvent preparation suitable concentration solution, as reference substance solution, according to spectrophotography, measures trap respectively in the wavelength of 260nm, calculates every respectively in the burst size of not watching the time.The slow releasing tablet of the present invention's preparation discharges 15%～30% in 30min accumulative total, 6h cumulative release 60%～75%, and the 12h cumulative release is more than 90%.
Specific embodiment
Data below in conjunction with embodiment and prescription study, verify are further set forth technical scheme of the present invention:
Embodiment 1
Prescription (by 1000)
Release layer:
Slow release layer:
Preparation technology
1.1 the particulate preparation of release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; With the abundant mixing of lactose, microcrystalline Cellulose, carboxymethyl starch sodium of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.2 the particulate preparation of slow release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; Then with the abundant mixing of HPMC K100M, ethyl cellulose, lactose, microcrystalline Cellulose of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.3 tabletting
Light earlier pressure release layer granule becomes loose, adds the extrusion forming of slow release layer granule again.
Embodiment 2
Prescription (by 1000)
Release layer:
Slow release layer:
Preparation technology
1.1 the particulate preparation of release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; With the abundant mixing of lactose, microcrystalline Cellulose, carboxymethyl starch sodium of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.2 the particulate preparation of slow release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; Then with the abundant mixing of HPMC K100M, ethyl cellulose, lactose, microcrystalline Cellulose of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.3 tabletting
Light earlier pressure release layer granule becomes loose, adds the extrusion forming of slow release layer granule again.
Embodiment 3
Prescription (by 1000)
Release layer:
Slow release layer:
Preparation technology
1.1 the particulate preparation of release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; With the abundant mixing of lactose, microcrystalline Cellulose, carboxymethyl starch sodium of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.2 the particulate preparation of slow release layer
Each component is crossed 100 mesh sieves respectively in will writing out a prescription; Then with the abundant mixing of HPMC K100M, ethyl cellulose, lactose, microcrystalline Cellulose of recipe quantity,, and be binding agent system soft material with an amount of 10%PVP K30 solution again with the abundant mixing of dexketoprofen trometamol; 20 mesh sieves are granulated; 60 ℃ of forced air dryings, 20 mesh sieve granulate add the magnesium stearate mixing again;
1.3 tabletting
Light earlier pressure release layer granule becomes loose, adds the extrusion forming of slow release layer granule again.
The double-layer sustained release tablets of a kind of dexketoprofen trometamol of three embodiment preparations, release characteristic is:
Three concrete release profiles of embodiment are seen Fig. 1.
According to the double-layer sustained release tablets that embodiment 1 adopts the HPMC of different size to prepare, its release characteristic is:
And the release profiles of the slow releasing tablet of these three kinds of different size HPMC is seen Fig. 2.
Three kinds of double-layer sustained release tablets according to embodiment 1 preparation carry out drug release determination respectively in three kinds of different media, be respectively phosphate buffer and the 0.1mol/L hydrochloric acid solution of distilled water, pH6.8, and its release characteristic is:
Release profiles in three kinds of different release medium is seen Fig. 3.
Claims (10)
1. dexketoprofen trometamol double-layer sustained release tablets; Comprise slow release layer and release layer; It is characterized in that: said slow release layer mainly is made up of dexketoprofen trometamol, disintegrating agent, diluent; Binding agent, lubricant is formed, and said slow release layer mainly is made up of dexketoprofen trometamol, slow-release material, diluent, binding agent, lubricant.
2. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1 is characterized in that: the effective dose of dexketoprofen trometamol is 10mg～120mg, and the ratio that release layer and slow release layer contain the principal agent amount is 1: (1～5).
3. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1; It is characterized in that said slow-release material can select one or more in hydroxypropyl methylcellulose, ethyl cellulose, methylcellulose, phthalic acid hydroxypropyl methylcellulose, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, cellulose diacetate, Triafol T, hexadecanol, glyceryl monostearate, Brazil wax, the hydroxy methocel for use, preferred hydroxypropyl methylcellulose and ethyl cellulose.
4. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1; One or more that it is characterized in that described disintegrating agent can select that cross linked polyvinyl pyrrolidone, carboxymethyl starch are received for use, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl cellulose are received, preferred cross-linked carboxymethyl cellulose is received.
5. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1; It is characterized in that described diluent can select lactose, pregelatinized Starch, microcrystalline Cellulose, mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol for use, gather in O-phthalic acid ethyl acetate, Polyethylene Glycol, the ethanol one or more, preferred lactose, microcrystalline Cellulose.
6. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1; It is characterized in that in the optional water of described binding agent, ethanol, dehydrated alcohol, starch slurry, polyvidone, cross linked polyvinyl pyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families one or more, preferred cross linked polyvinyl pyrrolidone.
7. dexketoprofen trometamol double-layer sustained release tablets as claimed in claim 1; Described double-layer sustained release tablets; It is characterized in that described lubricant can select one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, the sodium laurylsulfate for use, preferred magnesium stearate.
8. like the described dexketoprofen trometamol double-layer sustained release tablets of the arbitrary claim of claim 1～8, it is characterized in that counting by weight percentage, it consists of:
Release layer:
Slow release layer:
9. like the described dexketoprofen trometamol double-layer sustained release tablets of the arbitrary claim of claim 1～8, it is characterized in that comprising and be prepared as follows step:
The immediate-release granules preparation: each component that takes by weighing recipe quantity is crossed 100 mesh sieves respectively, then with crude drug, diluent, disintegrating agent mix homogeneously, with binding agent system soft material; 20 mesh sieve system wet granulars, 60 ℃ of forced air dryings, 20 mesh sieve granulate; Add the lubricant mixing, get the release layer granule.
The slow-releasing granules preparation: each component that takes by weighing recipe quantity is crossed 100 mesh sieves respectively, then with crude drug, slow-release material, diluent, mix homogeneously, with binding agent system soft material; 20 mesh sieve system wet granulars, 60 ℃ of forced air dryings, 20 mesh sieve granulate; Add the lubricant mixing, get the slow release layer granule.
Tabletting: light earlier pressure release layer granule becomes loose, adds the extrusion forming of slow release layer granule again, promptly gets double-layer tablet.
10. like the described dexketoprofen trometamol double-layer sustained release tablets of the arbitrary claim of claim 1～8, it is characterized in that said double-layer sustained release tablets is according to the device of dissolution method (2010 editions two appendix XC second methods of Chinese Pharmacopoeia); 900mL is a solvent with distilled water (pH7), and rotating speed is that per minute 100 changes, and temperature is 37 ℃; Operation in accordance with the law,, respectively at 0.5,1.0,2.0,4.0,6.0,8.0, the 12.0h sampling; Each 5mL;,, and in time in process container, replenish above-mentioned solvent with volume with the filtering with microporous membrane of aperture 0.45 μ m; And be mixed with finite concentration, as need testing solution; It is an amount of that precision takes by weighing the dexketoprofen trometamol reference substance in addition, with above-mentioned solvent preparation suitable concentration solution, as reference substance solution, according to spectrophotography, measures trap respectively in the wavelength of 260nm, calculates every burst size at different time respectively.The slow releasing tablet of the present invention's preparation discharges 15%～30% in 30min accumulative total, 6h cumulative release 60%～75%, and the 12h cumulative release is more than 90%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101500523A CN102813638A (en) | 2011-06-07 | 2011-06-07 | Preparation method of dexketoprofen trometamol double-layer sustained-release tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101500523A CN102813638A (en) | 2011-06-07 | 2011-06-07 | Preparation method of dexketoprofen trometamol double-layer sustained-release tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102813638A true CN102813638A (en) | 2012-12-12 |
Family
ID=47298325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101500523A Pending CN102813638A (en) | 2011-06-07 | 2011-06-07 | Preparation method of dexketoprofen trometamol double-layer sustained-release tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102813638A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106137997A (en) * | 2015-04-19 | 2016-11-23 | 浙江九洲药物科技有限公司 | A kind of dexketoprofen trometamol slow releasing tablet and preparation method thereof |
| WO2019212426A3 (en) * | 2017-12-29 | 2019-11-28 | Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi | Delayed release dexketoprofen composition |
| CN116350596A (en) * | 2022-12-02 | 2023-06-30 | 山东齐都药业有限公司 | Risperidone quick-release sustained-release double-release preparation and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60132915A (en) * | 1983-12-21 | 1985-07-16 | ロ−ン−プ−ラン・サント | Release controlled tablet for oral administration of ketoprofen and manufacture |
| EP0403383A1 (en) * | 1989-06-16 | 1990-12-19 | Rhone-Poulenc Sante | Sustained release pharmaceutical formulations |
| CN1260172A (en) * | 1998-12-18 | 2000-07-19 | 国家医药管理局上海医药工业研究院 | Dextro-betoprofen preparation |
| US20050118247A1 (en) * | 2000-07-05 | 2005-06-02 | Gunter Cordes | Method of making ketoprofen patch delivery system |
| CN101784262A (en) * | 2007-08-15 | 2010-07-21 | 麦克内尔-Ppc股份有限公司 | Immediate release and sustained release ibuprofen dosing regiment |
-
2011
- 2011-06-07 CN CN2011101500523A patent/CN102813638A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60132915A (en) * | 1983-12-21 | 1985-07-16 | ロ−ン−プ−ラン・サント | Release controlled tablet for oral administration of ketoprofen and manufacture |
| EP0403383A1 (en) * | 1989-06-16 | 1990-12-19 | Rhone-Poulenc Sante | Sustained release pharmaceutical formulations |
| CN1260172A (en) * | 1998-12-18 | 2000-07-19 | 国家医药管理局上海医药工业研究院 | Dextro-betoprofen preparation |
| US20050118247A1 (en) * | 2000-07-05 | 2005-06-02 | Gunter Cordes | Method of making ketoprofen patch delivery system |
| CN101784262A (en) * | 2007-08-15 | 2010-07-21 | 麦克内尔-Ppc股份有限公司 | Immediate release and sustained release ibuprofen dosing regiment |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106137997A (en) * | 2015-04-19 | 2016-11-23 | 浙江九洲药物科技有限公司 | A kind of dexketoprofen trometamol slow releasing tablet and preparation method thereof |
| CN106137997B (en) * | 2015-04-19 | 2020-06-05 | 瑞博(杭州)医药科技有限公司 | A kind of dexketoprofen tromethamine sustained-release tablet and preparation method thereof |
| WO2019212426A3 (en) * | 2017-12-29 | 2019-11-28 | Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi | Delayed release dexketoprofen composition |
| WO2020022976A3 (en) * | 2017-12-29 | 2020-03-12 | NEUTEC AR-GE SANAYİ VE TĺCARET ANONİM ŞİRKETİ | A formulation comprising dexketoprofen |
| CN116350596A (en) * | 2022-12-02 | 2023-06-30 | 山东齐都药业有限公司 | Risperidone quick-release sustained-release double-release preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250231B (en) | Pharmaceutical composition containing etoricoxib and preparation method thereof | |
| CN104146976B (en) | Heavy-load valproic acid drug sustained release tablet and preparation method thereof | |
| KR20100063090A (en) | Galenical formulations of aliskiren and valsartan | |
| CN102138911B (en) | Divalproex sodium sustained release tablets and preparation method thereof | |
| CN101229225A (en) | Salvia phenolic acid gastric retention preparation | |
| CN102813638A (en) | Preparation method of dexketoprofen trometamol double-layer sustained-release tablets | |
| CN104546732A (en) | Dexibuprofen sustained-release tablet and preparation process thereof | |
| JPWO2007123021A1 (en) | Method for producing sustained-release tablets | |
| CN105434386B (en) | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof | |
| CN102846573B (en) | Silibinin double-layer slow-release tablets and preparation method thereof | |
| CN102488670B (en) | Preparation method of dual slow-release potassium citrate sustained release preparation | |
| CN101342177B (en) | Lornoxicam double-layer sustained release tablets | |
| CN103655504B (en) | Dexketoprofen trometamol quick-release and slow-release double-layer tablet and preparation technology thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101658504A (en) | Paracetamol sustained-release double-layer tablets and preparation method thereof | |
| CN103385863A (en) | Sodium azulene sulfonate sustained-release preparation | |
| CN103301083B (en) | Nifedipine slow release tablet and preparation method thereof | |
| CN103690503B (en) | A kind of preparation method of double-layer tablet | |
| CN1785167A (en) | Method for preparing composite delayed-release prepn. of non-narcotic analgesic | |
| CN202314482U (en) | Ibuprofen delayed-release sandwiched tablet | |
| CN101244068B (en) | Hemsleyadin sustained release preparation | |
| CN103156822A (en) | Diclofenac sodium osmotic-pump controlled-release preparation and preparation method thereof | |
| CN201179204Y (en) | Slow-releasing pseudoephedrine buconazole capsule | |
| CN102552199A (en) | Bulleyaconitine a controlled release tablet | |
| CN103816131A (en) | Flurbiprofen double-layer osmotic pump controlled-release tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121212 |